Interferon pathway lupus risk alleles modulate risk of death from acute COVID-19. Academic Article uri icon

Overview

abstract

  • Type I interferon (IFN) is critical in our defense against viral infections. Increased type I IFN pathway activation is a genetic risk factor for systemic lupus erythematosus (SLE), and a number of common risk alleles contribute to the high IFN trait. We hypothesized that these common gain-of-function IFN pathway alleles may be associated with protection from mortality in acute COVID-19. We studied patients admitted with acute COVID-19 (756 European-American and 398 African-American ancestry). Ancestral backgrounds were analyzed separately, and mortality after acute COVID-19 was the primary outcome. In European-American ancestry, we found that a haplotype of interferon regulatory factor 5 (IRF5) and alleles of protein kinase cGMP-dependent 1 (PRKG1) were associated with mortality from COVID-19. Interestingly, these were much stronger risk factors in younger patients (OR = 29.2 for PRKG1 in ages 45-54). Variants in the IRF7 and IRF8 genes were associated with mortality from COVID-19 in African-American subjects, and these genetic effects were more pronounced in older subjects. Combining genetic information with blood biomarker data such as C-reactive protein, troponin, and D-dimer resulted in significantly improved predictive capacity, and in both ancestral backgrounds the risk genotypes were most relevant in those with positive biomarkers (OR for death between 14 and 111 in high risk genetic/biomarker groups). This study confirms the critical role of the IFN pathway in defense against COVID-19 and viral infections, and supports the idea that some common SLE risk alleles exert protective effects in antiviral immunity.

authors

  • Nln, Ilona
  • Fernandez Ruiz, Ruth
  • Muskardin, Theresa L Wampler
  • Paredes, Jacqueline L
  • Blazer, Ashira D
  • Tuminello, Stephanie
  • Attur, Mukundan
  • Iturrate, Eduardo
  • Petrilli, Christopher M
  • Abramson, Steven B
  • Chakravarti, Aravinda
  • Niewold, Timothy B

publication date

  • January 31, 2022

Research

keywords

  • COVID-19
  • Lupus Erythematosus, Systemic

Identity

PubMed Central ID

  • PMC8802623

Scopus Document Identifier

  • 85127344907

Digital Object Identifier (DOI)

  • 10.1136/annrheumdis-2020-219648

PubMed ID

  • 35114420

Additional Document Info

volume

  • 244